Does the media refer more to PAHC or GRFS?

In the previous week, Grifols had 1 more articles in the media than Phibro Animal Health. MarketBeat recorded 3 mentions for Grifols and 2 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 1.40 beat Grifols' score of 0.91 indicating that Phibro Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Grifols 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PAHC or INDV?

In the previous week, Phibro Animal Health and Phibro Animal Health both had 2 articles in the media. Phibro Animal Health's average media sentiment score of 1.40 beat Indivior's score of 0.72 indicating that Phibro Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Indivior 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PAHC or DNTH?

In the previous week, Phibro Animal Health and Phibro Animal Health both had 2 articles in the media. Dianthus Therapeutics' average media sentiment score of 1.89 beat Phibro Animal Health's score of 1.40 indicating that Dianthus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dianthus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor PAHC or ERAS?

In the previous week, Erasca had 31 more articles in the media than Phibro Animal Health. MarketBeat recorded 33 mentions for Erasca and 2 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 1.40 beat Erasca's score of 0.09 indicating that Phibro Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Erasca 2 Very Positive mention(s) 3 Positive mention(s) 26 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Phibro Animal Health (PAHC) Competitors

$32.02 +0.33 (+1.04%)

As of 11:29 AM Eastern

Compare

PAHC vs. GRFS, INDV, DNTH, ERAS, and KNSA

Should you buy Phibro Animal Health stock or one of its competitors? MarketBeat compares Phibro Animal Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Phibro Animal Health include Grifols (GRFS), Indivior (INDV), Dianthus Therapeutics (DNTH), Erasca (ERAS), and Kiniksa Pharmaceuticals International (KNSA). These companies are all part of the "pharmaceutical products" industry.

How does Phibro Animal Health compare to Grifols?

Phibro Animal Health (NASDAQ:PAHC) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

Phibro Animal Health pays an annual dividend of $0.48 per share and has a dividend yield of 1.5%. Grifols pays an annual dividend of $0.14 per share and has a dividend yield of 1.9%. Phibro Animal Health pays out 20.6% of its earnings in the form of a dividend. Grifols pays out 73.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Phibro Animal Health currently has a consensus target price of $42.50, suggesting a potential upside of 32.74%. Grifols has a consensus target price of $10.00, suggesting a potential upside of 35.61%. Given Grifols' higher probable upside, analysts plainly believe Grifols is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Grifols	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Phibro Animal Health has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market. Comparatively, Grifols has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

In the previous week, Grifols had 1 more articles in the media than Phibro Animal Health. MarketBeat recorded 3 mentions for Grifols and 2 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 1.40 beat Grifols' score of 0.91 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Grifols	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Grifols has higher revenue and earnings than Phibro Animal Health. Phibro Animal Health is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.50B	0.87	$48.26M	$2.33	13.74
Grifols	$8.51B	0.59	$454.82M	$0.19	38.81

99.3% of Phibro Animal Health shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by insiders. Comparatively, 0.2% of Grifols shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Phibro Animal Health has a net margin of 6.35% compared to Grifols' net margin of 5.54%. Phibro Animal Health's return on equity of 37.14% beat Grifols' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.35%	37.14%	8.57%
Grifols	5.54%	6.21%	2.39%

Summary

Phibro Animal Health beats Grifols on 11 of the 18 factors compared between the two stocks.

How does Phibro Animal Health compare to Indivior?

Phibro Animal Health (NASDAQ:PAHC) and Indivior (NASDAQ:INDV) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

Phibro Animal Health has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, Indivior has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

Indivior has lower revenue, but higher earnings than Phibro Animal Health. Phibro Animal Health is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.50B	0.87	$48.26M	$2.33	13.74
Indivior	$1.24B	4.04	$210M	$1.95	21.07

99.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by insiders. Comparatively, 0.7% of Indivior shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Phibro Animal Health and Phibro Animal Health both had 2 articles in the media. Phibro Animal Health's average media sentiment score of 1.40 beat Indivior's score of 0.72 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Phibro Animal Health presently has a consensus price target of $42.50, suggesting a potential upside of 32.74%. Indivior has a consensus price target of $40.29, suggesting a potential downside of 1.97%. Given Phibro Animal Health's higher possible upside, analysts clearly believe Phibro Animal Health is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

Indivior has a net margin of 19.44% compared to Phibro Animal Health's net margin of 6.35%. Phibro Animal Health's return on equity of 37.14% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.35%	37.14%	8.57%
Indivior	19.44%	-219.26%	29.40%

Summary

Indivior beats Phibro Animal Health on 9 of the 16 factors compared between the two stocks.

How does Phibro Animal Health compare to Dianthus Therapeutics?

Phibro Animal Health (NASDAQ:PAHC) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

In the previous week, Phibro Animal Health and Phibro Animal Health both had 2 articles in the media. Dianthus Therapeutics' average media sentiment score of 1.89 beat Phibro Animal Health's score of 1.40 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dianthus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by company insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Phibro Animal Health presently has a consensus price target of $42.50, indicating a potential upside of 32.74%. Dianthus Therapeutics has a consensus price target of $117.82, indicating a potential upside of 26.29%. Given Phibro Animal Health's higher probable upside, research analysts plainly believe Phibro Animal Health is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93

Phibro Animal Health has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.50B	0.87	$48.26M	$2.33	13.74
Dianthus Therapeutics	$1.34M	3,817.21	-$162.34M	-$4.13	N/A

Phibro Animal Health has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

Phibro Animal Health has a net margin of 6.35% compared to Dianthus Therapeutics' net margin of -12,998.50%. Phibro Animal Health's return on equity of 37.14% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.35%	37.14%	8.57%
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%

Summary

Phibro Animal Health beats Dianthus Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Phibro Animal Health compare to Erasca?

Phibro Animal Health (NASDAQ:PAHC) and Erasca (NASDAQ:ERAS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Phibro Animal Health has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, Erasca has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

Phibro Animal Health currently has a consensus target price of $42.50, suggesting a potential upside of 32.74%. Erasca has a consensus target price of $20.11, suggesting a potential upside of 18.49%. Given Phibro Animal Health's higher probable upside, analysts plainly believe Phibro Animal Health is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Erasca	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

99.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 67.8% of Erasca shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by company insiders. Comparatively, 14.2% of Erasca shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Phibro Animal Health has a net margin of 6.35% compared to Erasca's net margin of 0.00%. Phibro Animal Health's return on equity of 37.14% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.35%	37.14%	8.57%
Erasca	N/A	-35.31%	-29.49%

In the previous week, Erasca had 31 more articles in the media than Phibro Animal Health. MarketBeat recorded 33 mentions for Erasca and 2 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 1.40 beat Erasca's score of 0.09 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Erasca	2 Very Positive mention(s)	3 Positive mention(s)	26 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Phibro Animal Health has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.50B	0.87	$48.26M	$2.33	13.74
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A

Summary

Phibro Animal Health beats Erasca on 11 of the 15 factors compared between the two stocks.

How does Phibro Animal Health compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Phibro Animal Health (NASDAQ:PAHC) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

Kiniksa Pharmaceuticals International has higher earnings, but lower revenue than Phibro Animal Health. Phibro Animal Health is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	7.06	$59.01M	$0.90	69.06
Phibro Animal Health	$1.50B	0.87	$48.26M	$2.33	13.74

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Phibro Animal Health's net margin of 6.35%. Phibro Animal Health's return on equity of 37.14% beat Kiniksa Pharmaceuticals International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%
Phibro Animal Health	6.35%	37.14%	8.57%

Kiniksa Pharmaceuticals International presently has a consensus target price of $62.71, suggesting a potential upside of 0.89%. Phibro Animal Health has a consensus target price of $42.50, suggesting a potential upside of 32.74%. Given Phibro Animal Health's higher possible upside, analysts plainly believe Phibro Animal Health is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
Phibro Animal Health	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Kiniksa Pharmaceuticals International has a beta of 0.12, meaning that its stock price is 88% less volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market.

In the previous week, Kiniksa Pharmaceuticals International had 4 more articles in the media than Phibro Animal Health. MarketBeat recorded 6 mentions for Kiniksa Pharmaceuticals International and 2 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 1.40 beat Kiniksa Pharmaceuticals International's score of 1.29 indicating that Phibro Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Phibro Animal Health	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kiniksa Pharmaceuticals International beats Phibro Animal Health on 10 of the 17 factors compared between the two stocks.

Get Phibro Animal Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PAHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PAHC vs. The Competition

Export

Metric	Phibro Animal Health	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.30B	$8.46B	$6.85B	$12.33B
Dividend Yield	1.51%	2.47%	2.67%	6.11%
P/E Ratio	13.74	16.27	25.86	24.20
Price / Sales	0.87	5.62	550.66	101.54
Price / Cash	9.69	18.07	29.09	36.93
Price / Book	4.54	3.45	10.89	6.42
Net Income	$48.26M	$226.25M	$3.58B	$336.87M
7 Day Performance	3.05%	2.32%	2.51%	0.94%
1 Month Performance	3.99%	-3.05%	0.22%	-0.53%
1 Year Performance	24.78%	0.89%	35.34%	27.96%

Phibro Animal Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PAHC Phibro Animal Health	4.8366 of 5 stars	$32.02 +1.0%	$42.50 +32.7%	+23.5%	$1.30B	$1.50B	13.74	2,475	Upcoming Earnings
GRFS Grifols	4.5684 of 5 stars	$7.18 -1.4%	$10.00 +39.3%	-16.2%	$4.89B	$8.51B	37.79	25,247
INDV Indivior	2.1559 of 5 stars	$39.97 +4.3%	$40.29 +0.8%	+199.9%	$4.87B	$1.24B	20.50	1,051
DNTH Dianthus Therapeutics	3.0808 of 5 stars	$87.53 +0.2%	$117.82 +34.6%	+440.8%	$4.78B	$1.34M	N/A	80	Positive News
ERAS Erasca	2.2572 of 5 stars	$15.07 -0.1%	$20.11 +33.5%	+1,123.3%	$4.69B	N/A	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PAHC) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Phibro Animal Health (PAHC) Competitors

PAHC vs. GRFS, INDV, DNTH, ERAS, and KNSA

How does Phibro Animal Health compare to Grifols?

Summary

How does Phibro Animal Health compare to Indivior?

Summary

How does Phibro Animal Health compare to Dianthus Therapeutics?

Summary

How does Phibro Animal Health compare to Erasca?

Summary

How does Phibro Animal Health compare to Kiniksa Pharmaceuticals International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PAHC vs. The Competition

Phibro Animal Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Phibro Animal Health (PAHC) Competitors

PAHC vs. GRFS, INDV, DNTH, ERAS, and KNSA

How does Phibro Animal Health compare to Grifols?

Is PAHC or GRFS a better dividend stock?

Do analysts prefer PAHC or GRFS?

Which has more risk and volatility, PAHC or GRFS?

Does the media refer more to PAHC or GRFS?

Which has higher valuation and earnings, PAHC or GRFS?

Do insiders and institutionals hold more shares of PAHC or GRFS?

Is PAHC or GRFS more profitable?

Summary

How does Phibro Animal Health compare to Indivior?

Which has more risk & volatility, PAHC or INDV?

Which has preferable earnings and valuation, PAHC or INDV?

Do institutionals & insiders have more ownership in PAHC or INDV?

Does the media favor PAHC or INDV?

Do analysts recommend PAHC or INDV?

Is PAHC or INDV more profitable?

Summary

How does Phibro Animal Health compare to Dianthus Therapeutics?

Does the media favor PAHC or DNTH?

Do insiders & institutionals believe in PAHC or DNTH?

Do analysts rate PAHC or DNTH?

Which has stronger earnings & valuation, PAHC or DNTH?

Which has more risk and volatility, PAHC or DNTH?

Is PAHC or DNTH more profitable?

Summary

How does Phibro Animal Health compare to Erasca?

Which has more volatility and risk, PAHC or ERAS?

Do analysts prefer PAHC or ERAS?

Do insiders & institutionals have more ownership in PAHC or ERAS?

Is PAHC or ERAS more profitable?

Does the media favor PAHC or ERAS?

Which has higher valuation and earnings, PAHC or ERAS?

Summary

How does Phibro Animal Health compare to Kiniksa Pharmaceuticals International?

Which has better earnings & valuation, KNSA or PAHC?

Is KNSA or PAHC more profitable?

Do analysts prefer KNSA or PAHC?

Do institutionals and insiders hold more shares of KNSA or PAHC?

Which has more volatility & risk, KNSA or PAHC?

Does the media refer more to KNSA or PAHC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PAHC vs. The Competition

Phibro Animal Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools